时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Abdominal aortic aneurysm (AAA) is a degenerative condition involving several processes including inflammation, matrix remodeling, disruptions of vascular smooth muscle cells, and thrombus formation all leading to progressive dilatation of the aorta and eventual rupture. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are now considered part of the frontline therapeutic options to treat type 2 diabetes mellitus and have also been validated as having compelling anti-inflammatory and cardiovascular protective properties. Data is limited on the impact of GLP-1RA on outcomes of patients with AAA. The aim of this study is to examine the association and possible impact of GLP-1RA on patients with AAA.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★☆☆☆☆ 血管老化提供可影像量化、可短期读取的中间终点，适合做机制到临床的桥接。最大样本量约 412,490。
原文题录
- 英文标题：GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.
- 期刊与标识：J Vasc Surg · PMID 42957066 · DOI 10.1016/j.jvs.2026.09.053
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。